DUBLIN--(BUSINESS WIRE)--The "US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026" report has been added to ResearchAndMarkets.com's offering. The complete research report is divided ...
LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant ...
About the Ketabon Program The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma comprises an oral prolonged-release formulation of ketamine for TRD (KET01) with minimal ...
VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The growing use of ketamine to ease depression has been boosted by research that found giving the drug in ...
Dosages for the Phase IIa programme were selected following the successful completion of the double-blind stage of Beckley Psytech’s Phase I study earlier this year, which showed that BPL-003 was well ...
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...
MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its ...
VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL) (OTC: CLABD) (Frankfurt: LD6, WKN:A3CSSU) (the “Company”) is excited to announce that its wholly owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback